Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...

Cabaletta Bio’s financials and CAR T-cell therapy show potential but face risks. Discover why CABA stock is a risky yet ...

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares.

CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM). According to GlobalData, Phase II drugs for Idiopathic Inflammatory ...

In a phase III clinical trial of abatacept for idiopathic inflammatory myopathy, the primary endpoint was not met but the results suggest abatacept could have benefits in some subtypes of the disease.

Ustad Hussain’s family, in a statement, said he died of idiopathic pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is a disease that causes scarring of the lungs. This scarring causes ...